The Kilkenny, Ireland facility will focus on the global manufacturing of sensors for Abbott’s CGM diabetes devices.

FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

Abbott's Freestyle Libre 2 and 3 are the first CGMs to receive FDA clearance for use during imaging tests like X-rays, CT ...

Abbott announced today that it officially opened a new state-of-the-art manufacturing facility in Kilkenny, Ireland.

More than 800 people will be employed at the plant, which will make more Libre sensors than any of the company’s other facilities.

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Abbott on Nov. 18 held a ceremony to celebrate the official opening of a state-of-the-art manufacturing facility in Kilkenny, ...

Historically, providers would need to log into separate portals or support different workflows for each CGM manufacturer to review the data from their patients. Additionally, it was cumbersome to ...

Abbott (NYSE: ABT) today marked the official opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland with ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous data streams, according to some industry experts.

Diabetes educators play an essential role in helping patients achieve optimal health outcomes through personalized support ...